Welcome to our dedicated page for TuHURA Biosciences SEC filings (Ticker: HURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science behind IFx-2.0 is exciting, yet decoding TuHURA Biosciences’ regulatory paperwork is another story. Investors routinely Google “Where can I find the TuHURA Biosciences quarterly earnings report 10-Q filing?” or “How do I monitor TuHURA Biosciences insider trading Form 4 transactions?” The answers sit inside hundreds of pages packed with immuno-oncology jargon. Stock Titan gathers every submission in one place and offers TuHURA Biosciences SEC filings explained simply, including TuHURA Biosciences Form 4 insider transactions real-time so you focus on data, not downloads.
Stock Titan’s AI-powered summaries parse complex biotech language and surface what matters: trial milestones, cash runway, dilution risk, and partnership revenue. Need TuHURA Biosciences earnings report filing analysis before the call? Prefer understanding TuHURA Biosciences SEC documents with AI instead of reading footnotes? The platform delivers concise briefs and contextual charts. Real-time alerts flag TuHURA Biosciences executive stock transactions Form 4 moments after they hit EDGAR, giving you a timely read on management sentiment.
Every filing type is covered and linked to the questions investors actually ask:
- TuHURA Biosciences annual report 10-K simplified—key risk factors, R&D spend, and cash runway in plain language
- TuHURA Biosciences proxy statement executive compensation—clear tables showing how milestone-based pay aligns with shareholder value
- TuHURA Biosciences 8-K material events explained—real-time summaries of trial updates, financings, or partnership announcements
With real-time filing updates, AI insights, and expert context, Stock Titan turns TuHURA Biosciences’ disclosures into actionable knowledge—saving analysts hours and supporting confident decisions.
TuHURA Biosciences' amended S-1 (S-1/A) describes a clinical-stage biopharma focused on innate and tumor microenvironment immunotherapies. The filing notes initiation of a Phase 3 trial of IFx-2.0 in June 2025 using the FDA accelerated approval pathway and reports prior early-stage data: 23 patients enrolled in an IFx-2.0 study with no grade 3+ toxicities, a recommended Phase 2 dose, a 48% disease control rate at injected lesions at 28 days and a post-protocol objective response rate of 64% (7 of 11) in Merkel cell carcinoma after ICI rechallenge. TuHURA acquired Kineta assets including TBS-2025 (VISTA antibody) in June 2025 and plans a randomized Phase 2 in mutNPM1 AML (menin inhibitor ± TBS-2025) to start in late Q4 2025. Financial disclosures state the company has no product revenue, substantial operating losses, a going concern qualification and material non-cash charges (~$16.9M, including a $16.2M IPR&D write-off). The S-1/A also details a prior merger transaction structure and executive employment and compensation terms.
FAQ
What is the current stock price of TuHURA Biosciences (HURA)?
What is the market cap of TuHURA Biosciences (HURA)?
